Reply to Dr. Megarbane et al. regarding "Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose"

Megarbane et al. suggest in their letter that pharmacokinetic–pharmacodynamic (PKPD) analysis in individual patients is the only way to quantify the time-course of in vivo drug effects in overdose patients. Although the analysis of a single case may provide some information that can be used to generate hypotheses for future studies, it is not possible to gain an understanding of variability within the population or of patient characteristics that may explain some of this variability